Back to Agenda
Session 10: What might the future of evidence generation and use look like?
Session Chair(s)
Thomas Brookland, MSC
Regulatory Science and Policy Lead, F. Hoffmann-La Roche Ltd, Switzerland
Increasing interest and excitement in the potential of health data and evidence within the healthcare community has been triggered by a number of developments, including the greater availability and quality of electronic healthcare information, the emergence of tools for advanced analysis of large data volumes (greater computing power, data handling and analysis techniques) and the ability to link data from multiple sources.
There are a multitude of European initiatives and projects ongoing in this data and evidence generation space, a number of which are being driven by the European Institutions and Regulatory bodies. However, the scope and objectives of these projects often seem to be framed within the next 3 – 5 years, with numerous goals citing 2025 as a target date.
This final session of the workshop will take a look at data and evidence generation a little further into the future and ask what might this space look like in the next 10 – 15 years time and what opportunities, challenges and policy implications may come with this that we should already be thinking about now.
Speaker(s)
Alison Cave
Chief Safety Officer, Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom
Panel Discussion and Q&A
Cécile Mathilde Ollivier, MS
Vice President, Global Affairs - Managing Director, Europe, Critical Path Institute, Netherlands
Contributing Panelist
Irene Nunes, PHD
VP, Head of Regulatory Affairs, Flatiron Health, United States
Contributing Panelist
Frank Petavy, MS
Head of Methodology, European Medicines Agency, Netherlands
Contributing Panelist
Jesper Kjær, MS
Global Director for Public, Private Partnerships, Strat Ops, Global Med Affairs, Novo Nordisk A/S, Denmark
Contributing Panelist
Have an account?